Atea Pharma grants options and RSUs to director
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation.
Rhea-AI Filing Summary
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation. On June 18, 2026, he was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026, and are fully vested on June 18, 2027, if he continues serving the company.
He also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 64,400 shares
Grant/Award
2 txns
Insider
Berman Howard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 26,700 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 37,700 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 26,700 contracts (Direct);
Stock Option (Right to Buy) — 37,700 contracts (Direct)
Footnotes (3)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
- F3. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
Key Figures
Stock options granted: 37,700 shares
Option exercise price: $4.36 per share
Option expiration: June 17, 2036
+3 more
6 metrics
Stock options granted
37,700 shares
Grant of stock options on June 18, 2026
Option exercise price
$4.36 per share
Exercise price for 37,700 options granted
Option expiration
June 17, 2036
Expiration date of granted stock options
RSUs granted
26,700 units
Restricted stock units granted on June 18, 2026
Option vesting end date
June 18, 2027
Date options are fully vested if service continues
RSU vesting trigger
Next annual meeting after June 18, 2026 or June 18, 2027
Single-installment vesting condition for RSUs
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), contingent right, vest
4 terms
Restricted Stock Units financial
"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with an exercise price of 4.3600 per share"
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share..."
vest financial
"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Form 4 for Atea Pharmaceuticals (AVIR) report?
The Form 4 reports that director Howard Berman received equity compensation, including stock options and restricted stock units. These awards increase his potential ownership in Atea Pharmaceuticals, subject to time-based vesting and continued service conditions over the coming year.
How many stock options did Howard Berman receive from Atea Pharmaceuticals (AVIR)?
Howard Berman received stock options for 37,700 shares of Atea Pharmaceuticals common stock at a $4.36 exercise price. These options vest in twelve substantially equal monthly installments after June 18, 2026, becoming fully vested on June 18, 2027, if he remains in service.
What restricted stock unit (RSU) grant did Atea Pharmaceuticals (AVIR) make to Howard Berman?
Atea Pharmaceuticals granted Howard Berman 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
When do Howard Berman’s new Atea Pharmaceuticals (AVIR) equity awards vest?
The stock options vest in twelve substantially equal monthly installments following June 18, 2026 and are fully vested on June 18, 2027. The 26,700 RSUs vest in one installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027.
What is the exercise price and expiration date of Howard Berman’s Atea Pharmaceuticals (AVIR) options?
The stock options granted to Howard Berman have an exercise price of $4.36 per share and an expiration date of June 17, 2036. He can exercise vested options any time before expiration, subject to the company’s plan rules and applicable regulations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
